for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sino Biopharmaceutical Limited

1177.HK

Latest Trade

8.41HKD

Change

-0.15(-1.75%)

Volume

44,317,915

Today's Range

8.38

 - 

8.65

52 Week Range

6.17

 - 

11.24

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
8.56
Open
8.50
Volume
44,317,915
3M AVG Volume
1,614.20
Today's High
8.65
Today's Low
8.38
52 Week High
11.24
52 Week Low
6.17
Shares Out (MIL)
18,872.63
Market Cap (MIL)
161,927.10
Forward P/E
44.05
Dividend (Yield %)
0.70

Next Event

Q3 2020 Sino Biopharmaceutical Ltd Earnings Release

Latest Developments

More

Sino Biopharmaceutical Says "Spironolactone Tablets" Obtained Notice Of Approval By NMPA Of PRC

Sino Biopharmaceutical Says "Saxaglipin Tablets" Got Drug Registration Certificate From NMPA

Sino Biopharmaceutical Says "TDI01" Clinical Trial Application Accepted By CDE Of PRC

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

Unit 09, 41F, Office Tower

Convention Plaza, No. 1 Harbour Road

Wanchai

Hong Kong

+852.null.28029886

http://www.sinobiopharm.com/

Executive Leadership

Y Y Tse

Executive Chairwoman of the Board

Yi Li

Chief Executive Officer, Executive Director

Cheung Ling Cheng

Executive Vice Chairwoman of the Board

Ping Tse

Senior Executive Vice Chairman of the Board

Jiayin Ma

Group Chief Financial Officer

Key Stats

1.79 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

14.8K

2018

20.9K

2019

24.2K

2020(E)

27.0K
EPS (CNY)

2017

0.130

2018

0.153

2019

0.167

2020(E)

0.169
Price To Earnings (TTM)
57.48
Price To Sales (TTM)
5.86
Price To Book (MRQ)
4.53
Price To Cash Flow (TTM)
23.48
Total Debt To Equity (MRQ)
46.85
LT Debt To Equity (MRQ)
45.76
Return on Investment (TTM)
11.01
Return on Equity (TTM)
7.43

Latest News

Latest News

Hong Kong shares end higher after Wall Street's tech bounce

Hong Kong shares emulated Wall Street's rebound to end higher on Wednesday, though persistent investor concerns about the prospects of fresh Sino-U.S. trade tensions and a slower-than-expected global economic growth capped gains. ** At the close of trade, the Hang Seng index...

BRIEF-Sino Biopharmaceutical Says "Invert Sugar Injection" Got Approval For Drug Registration

* "INVERT SUGAR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION

BRIEF-Sino Biopharma Says Clopidogrel Bisulfate Tablet Obtained Approval For Drug Registration By NMPA

* SINO BIOPHARMACEUTICAL LTD- CLOPIDOGREL BISULFATE TABLET OBTAINED APPROVAL FOR DRUG REGISTRATION GRANTED BY NMPA OF PRC Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharma Proposes Bonus Issue Of Shares

* PROPOSES A BONUS ISSUE OF SHARES ON BASIS OF ONE NEW SHARE FOR EVERY TWO EXISTING SHARES HELD BY QUALIFYING SHAREHOLDERS Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Gets Approval For Aids Treatment Drug

* GETS APPROVAL FOR AIDS TREATMENT DRUG DEVELOPED BY GROUP FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Says Qtrly Profit Attributable RMB862.02 Mln, Up 0.6%

* DECLARED QUARTERLY DIVIDEND OF HK2 CPS Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Gets NMPA Approval for "Edaravone And Sodium Chloride Injection"

* "EDARAVONE AND SODIUM CHLORIDE INJECTION" GETS APPROVAL FOR SUPPLEMENTARY DRUG REGISTRATION BY NMPA OF PRC Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Says Anti Pd-1 Monoclonal Antibody Drug Accepted By NMPA

* ANTI PD-1 MONOCLONAL ANTIBODY DRUG ACCEPTED BY NMPA Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Says Vildagliptin Tablets Gets NMPA Approval For Registration

* "VILDAGLIPTIN TABLETS", ORAL HYPOGLYCEMIC DRUG GETS APPROVAL FOR REGISTRATION BY NMPA OF PRC Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Sino Biopharmaceutical Posts FY Profit Attributable Of RMB 2,706.79 Mln

* FY PROFIT ATTRIBUTABLE ABOUT RMB2,706.79 MILLION, DOWN 70.1%

BRIEF-Sino Biopharmaceutical Says Dabigatran Etexilate Capsules Developed By Unit Gets Approval For Drug Registration Granted By NMPA

* SINO BIOPHARMACEUTICAL LTD- DABIGATRAN ETEXILATE CAPSULES DEVELOPED BY UNIT OBTAINED APPROVAL FOR DRUG REGISTRATION GRANTED BY NMPA OF PRC Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Unit Signs "Collaboration In Ai Technology For Innovative Oncology Drug Discovery"

* UNIT SIGNS "COLLABORATION IN AI TECHNOLOGY FOR INNOVATIVE ONCOLOGY DRUG DISCOVERY" WITH INSILICO MEDICINE Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceuticaln Updates On Obtaining Approval For Drug Registration Of Injection

* MOXIFLOXACIN HYDROCHLORIDE & SODIUM CHLORIDE INJECTION OBTAINED APPROVAL FOR DRUG REGISTRATION GRANTED BY NMPA Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Says "Sitagliptin Phosphate Tablet" By Unit Gets NMPA Registration Approval

* "SITAGLIPTIN PHOSPHATE TABLET" DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NMPA OF PRC Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Sino Biopharmaceutical Unit's Drug Gets Approval For Drug Registration

* BUDESONIDE SUSPENSION FOR INHALATION, A DRUG DEVELOPED BY UNIT OBTAINED APPROVAL FOR DRUG REGISTRATION GRANTED BY NMPA Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Updates On Unit's Magnesium Isoglycyrrhizinate

* MAGNESIUM ISOGLYCYRRHIZINATE INCLUDED IN TREATMENT PRACTICES FOR NOVEL CORONAVIRUS PNEUMONIA (2ND EDITION) Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Says Application For New Indication Of Brain Neuroprotective Agent Accepted By NMPA

* APPLICATION FOR A NEW INDICATION OF "EDARAVONE AND SODIUM CHLORIDE INJECTION" FILED WITH & ACCEPTED BY NMPA OF PRC Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical Says "Fulvestrant Injection" Gets FDA ANDA Approval

* "FULVESTRANT INJECTION" GETS FDA ANDA APPROVAL & GERMANY BFARM MARKETING AUTHORIZATION Source text for Eikon: Further company coverage:

China Resources Gas, Sino Biopharmaceutical to join Hang Seng China Enterprises Index

Hong Kong's stock index compiler said on Friday that China Resources Gas Group Ltd and Sino Biopharmaceutical Ltd have been selected to join the Hang Seng China Enterprises Index, while two companies will be removed.

BRIEF-Sino Biopharmaceutical Co Announces Acquisition of Sino Biopharm Beijing​ & Super Demand

* CO TO ACQUIRE SINO BIOPHARM BEIJING,WHICH OWNS 33.6% OF BEIJING TIDE, BY ISSUING 723.3 MILLION SHARES AT HK$12.73 PER ISSUE SHARE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up